Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led bybetter than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn.